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Abstract
Background:  FAT10 is a member of the ubiquitin-like-modifier family of proteins. Over-
expression of the FAT10 gene was observed in the tumors of several epithelial cancers. High
FAT10 expression was found to lead to increased chromosome instability via the reduction in the
kinetochore localization of MAD2 during the prometaphase stage of the cell-cycle. FAT10
expression was also previously reported to be regulated by cytokines and p53.
Results: Here, we report that FAT10 expression is regulated at the protein and transcript level
during cell-cycle with highest expression observed during the S-phase of the cell-cycle. The distal
region between -1997 to -975 bp from the transcription start site of the FAT10 promoter may play
a role in the repression of FAT10 expression during G2/M phase of the cell-cycle.
Conclusion: FAT10 expression is regulated during cell-cycle.
One of the hallmarks of cancer is the deregulation of cell-
cycle controls [1,2]. The cell-cycle is the timed sequence of
events by which a cell duplicates all its components and
produces two daughter cells. Successful progression
through the cell cycle requires sequential activation of a
variety of catalytic subunits called cyclin-dependent
kinases (Cdks) that are dependent on the periodic synthe-
sis of cell-cycle specific regulatory subunits known as cyc-
lins [3]. The orderly transitions between the cell cycle
phases are regulated by the proteolysis of cyclins; inhibi-
tory phosphorylation of both Cdks and cyclins; as well as
by the interaction with inhibitory regulators in a timely
fashion [3]. Proteolytic destruction of cyclin proteins
occurs through the 26S proteasome pathway, a process
whereby each protein is covalently conjugated to an ubiq-
uitin chain at one or more lysine residues, which serves as
the signal for targeting the protein to the 26S proteasome
for degradation [3,4]. Defects in the ubiquitin system can
lead to a plethora of diseases, including many cancers. For
instance, MDM2, an ubiquitin ligase, was found to be
amplified in human sarcomas, gliomas, breast carcino-
mas and leukemias [5-9], probably by deregulating the
p53-dependent tumor suppression pathway [10].
While ubiquitin is a key regulator of the cell cycle, a grow-
ing group of related low-molecular-weight proteins
known as ubiquitin-like proteins have been identified
within the last few years that are implicated in diverse cel-
lular processes. To date, two families of ubiquitin-like
proteins are recognized, namely the ubiquitin-like modi-
fiers (UBLs) and ubiquitin-domain proteins (UDPs) [11].
As their family name suggests, they have regions of
homology with the 76 amino acids of the ubiquitin pro-
tein, but are otherwise unrelated to each other. Like ubiq-
uitin, the UBL family, for example, SUMO/Sentrin and
NEDD8/Rub1, function as modifiers by conjugation to
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other proteins. The UDP proteins, such as RAD23 and
Elongin B, on the other hand, are not covalently attached
to target proteins although they contain ubiquitin homol-
ogy domains [11].
FAT10, also known as diubiquitin, belongs to the UBL
class of ubiquitin-like proteins. Initially identified as one
of the genes at the major histocompatibility complex
locus in human chromosome 6 [12], the FAT10 gene
encodes an 18 kDa protein containing 165 amino acid
residues that shares 29% and 36% identity with ubiquitin
at the N- and C-terminus, respectively. Although its func-
tion has not been fully elucidated, it has been implicated
to play important roles in various cellular processes.
Like ubiquitin [13], FAT10 also functions as a proteina-
ceous tag, which when attached to a substrate protein, tar-
gets it to the 26S proteasome for degradation [14]. While
ubiquitin is recycled from the degraded target proteins,
FAT10 has a relatively short half-life and is degraded
together with its target [14]. The binding of the NEDD8
ultimate buster 1 long (NUB1L) protein to FAT10 was
found to further accelerate the degradation of FAT10 [15].
Knockout of the FAT10 gene in mice causes minimal phe-
notypic changes. These mice exhibit increased sensitivity
to endotoxin challenge and their lymphocytes are more
susceptible to spontaneous apoptotic death [16].
On the other hand, over-expression of the FAT10 gene was
observed in the tumors of several cancers including gas-
trointestinal and gynecological cancers [17]. High level of
the FAT10 protein in cells was recently found to lead to
increased mitotic non-dysjunction and chromosome
instability [18]. FAT10 was shown to interact with the
mitotic checkpoint protein, MAD2, during the mitotic
phase of the cell-cycle [18]. An abbreviated mitotic phase
and a reduction in the kinetochore localization of the
MAD2 protein during the prometaphase stage of the cell-
cycle was also observed in cells expressing high levels of
the FAT10 protein [18].
Expression of the FAT10 gene was reported to be up-regu-
lated by cytokines IFN-γ and TNF-α [12,19,20]. FAT10
expression was recently shown to be negatively regulated
by p53 [21], which plays important roles in the regulation
of the cell-cycle [22]. The abnormally high expression of
FAT10 in the tumors of several cancers, coupled with the
observation that high FAT10 levels in cells lead to mitotic
non-dysjunction and chromosome instability through the
reduction of the MAD2 kinetochore localization during
the pro-metaphase stage of the cell-cycle; as well as the
findings that its expression is positively regulated by TNF-
α, a presumptive tumor promoter [14,23], but negatively
regulated by p53, the "guardian-of-the-genome" [24],
together, strongly implicate the important role that FAT10
plays in cell-cycle control and tumorigenesis. Since many
genes that are involved in cell-cycle regulation are, them-
selves, regulated in a cell-cycle dependent fashion [25,26],
in this study, we examine if the expression of the FAT10
gene is also regulated in a cell-cycle dependent manner.
Results and discussion
FAT10 expression in HCT116 human colon carcinoma cells 
is cell cycle-regulated at the transcript level
The finding that the FAT10 gene expression is negatively
regulated by p53 [21], which is known to play an impor-
tant role in cell-cycle regulation; coupled with the obser-
vation of the over-expression of the FAT10 gene in the
tumors of various cancers [17], as well as the demonstra-
tion that abnormally high levels of FAT10 in HCT116 cells
can disrupt cell-cycle controls leading to chromosome
instability [18], suggested that the endogenous FAT10
expression may be regulated throughout the normal cell
cycle. To address if the FAT10 gene is itself regulated in a
cell-cycle dependent manner, populations of HCT116
cells were blocked at G1, S, or M phase of the cell cycle and
the expression of the FAT10 gene at the protein and tran-
script levels were examined by Western blot analyses and
reverse-transcription (RT) real-time PCR. The cell cycle
stage of each HCT116 population was determined by flow
cytometric analysis of the DNA content in the cell popula-
tion (Fig. 1A). As shown in Fig. 1B, FAT10 protein expres-
sion peaks in S phase of the cell cycle and then decreased
when cells were arrested at the G2/M border in nocoda-
zole. Similar and more statistically significant trends were
observed at the transcript/mRNA level (Fig. 1C). The
observation of lower FAT10 expression at the G2/M bor-
der of the cell-cycle stage is consistent with parental
HCT116 cells maintaining low levels of FAT10 during the
G2/M phase of the cell-cycle to preserve chromosome sta-
bility by preventing FAT10 from interacting with MAD2
and reducing the kinetochore localization of MAD2 dur-
ing this stage of cell-cycle which may lead to mitotic non-
dysjunction and chromosome instability.
The promoter of FAT10 plays a role in the cell-cycle-
regulated expression of FAT10
Since FAT10 expression was found to be cell-cycle regu-
lated at the transcript level, we examined the promoter of
FAT10 to determine if it plays a role in the cell-cycle regu-
lation of FAT10 expression and to delineate the region of
the promoter that may be responsible for the cell-cycle
regulation of FAT10 expression. We previously delineated
the regions of the FAT10 promoter that mediate promoter
activities in Hep3B, HepG2 and KB3-1 cells [21]. In this
study, we examined FAT10 promoter activities in HCT116
cells whose FAT10 expression is cell-cycle regulated at
both the protein (Fig. 1B) and the transcript levels (Fig.
1C) and which we previously reported that artificial over-Cell Division 2006, 1:20 http://www.celldiv.com/content/1/1/20
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expression of the FAT10 gene in these cells results in chro-
mosome instability [18]. As evident in Figure 1E (left
panel), maximum FAT10 promoter activity was observed
in HCT116 cells when FAT(-1997/+209) and FAT(-975/
+209) promoter region was cloned upstream the β-galac-
tosidase reporter and significantly lower promoter activity
was found when FAT(-366/+209) and FAT(+1/+209) was
cloned upstream the reporter. Hence, the trend of FAT10
promoter activities observed for HCT116 cells were simi-
lar to those previously reported for Hep3B, HepG2 and
KB3-1 cells although the absolute promoter activity in
HCT116 which is p53+ was more similar to p53+HepG2
and KB3-1 cells and approximately 22–30 fold lower than
the FAT10 promoter activity in p53- Hep3B cells [21].
FAT10 expression at the transcript level and promoter is cell-cycle regulation in HCT116 cells Figure 1
FAT10 expression at the transcript level and promoter is cell-cycle regulation in HCT116 cells. (A) Cell-cycle 
profiles of HCT116 cells synchronized at the various cell-cycle stages: C – Asynchronous cells; G1-Cells synchronized to G1-
phase with L-minosine; S-Cells syncrhonized to S-phase with Thymidine and G2/M-Cells synchronized to G2/M phase with 
nocodazole. (B) FAT10 protein expression normalized against β-actin protein levels. Top panel: Western blot of a representa-
tive experiment. Bottom panel: mean and standard deviation of results quantitated from Western blots from three independ-
ent experiments. *p < 0.05. (C) FAT10 mRNA transcript levels normalized against β-actin mRNA levels. Results shown are the 
mean and standard deviation from three independent experiments. *p < 0.05 and **p < 0.01. (D) Promoter-reporter construct 
used to assay FAT10 promoter activity. Various lengths of the FAT10 promoter drive the β-galactosidase reporter gene while 
the constitutive CMV promoter drives the EGFP to normalize for differences in transfection efficiencies. (E) Left panel – FAT10 
promoter activity in HCT116 cells expressed as normalized β-galactosidase activity from 3 independent experiments. Middle 
Panel – Pictorial representation of the various regions of DNA upstream and downstream the transcription start site of the 
FAT10 gene that is cloned before the β-galactosidase gene. Right Panel – FAT10 promoter activity in HCT116 cells synchro-
nized to the various cell-cycle stages (white: G2/M; black: S and Grey: G1) in HCT116 cells. Results shown are the mean and 
standard deviation from three independent experiments.
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To determine the region of the FAT10 promoter that may
mediate cell-cycle regulation, the four constructs carrying
different lengths of the FAT10 promoter upstream the β-
galactosidase reporter were transfected into HCT116 cells
and treated with mimosine, thymidine, or nocodazole to
arrest them in G1, S or M phase, respectively, 24 h later.
Flow cytometric analyses of DNA were used to confirm
the cell-cycle stage of the transfected cells (Fig 1A). Similar
to our observation of FAT10 mRNA expression at the dif-
ferent phase of the cell-cycle, when the longest promoter
fragment (FAT(-1997/+209)) was cloned upstream the β-
galactosidase reporter, highest FAT10 promoter activity
was observed in S-phase but not in G1 or G2/M phases
(Fig. 1E, right panel). However, when the distal promoter
region was deleted to -975 bp from the transcription start
site (TSS) (FAT(-975/+209)), the repression of the FAT10
promoter activity at the G2/M phase of the cell-cycle was
relieved while its activity at the G1 phase remain low (Fig.
1E, right panel). Hence, the distal promoter region
between -1997 and -975 bp from the TSS may play a role
in the inhibiting FAT10 expression during the G2/M
phase of the cell-cycle.
In light of our earlier observations that over-expression of
the FAT10 gene in HCT116 cells will result in the reduc-
tion of the kinetochore localization of the important
checkpoint MAD2 protein leading to mitotic non-dys-
junction and chromosome instability [18], our current
observation that FAT10 expression, through the repres-
sion of the FAT10 promoter activity, is kept low during
G2/M phase of cell-cycle is notable. It suggests that cells
may have evolved to ensure the fidelity of its cell-division
by repressing the expression of proteins like FAT10 which
might interact and interfere with the functions of impor-
tant checkpoint proteins like MAD2 during the G2/M
phase of the cell-cycle. Repression of the FAT10 gene is
observed at two levels, the first general major repression is
carried out by the p53 protein [21] and the second more
specific repression is observed at the G2/M phase of the
cell-cycle where FAT10 was shown to interact with mitotic
checkpoint protein, MAD2. De-regulation of the expres-
sion of these proteins like FAT10 would result in the de-
regulation of the G2/M cell-cycle phase controls resulting
in the abberant distribution of chromosomes during cell-
division, hence, leading to tumorigenesis.
Materials and methods
Cell lines and tissue culture
HCT116 (colon carcinoma) cells were purchased from
American Type Culture Collection and grown in McCoy's
5A (Sigma) supplemented with 10% fetal calf serum at
37°C in a humidified atmosphere of 5% CO2.
Cell cycle synchronization and flow cytometry
Synchronization of HCT116 cells at the various cell cycle
stages was performed according to a protocol described by
Su et al [27]. Briefly, cells were initially synchronized to
the same cell-cycle phase by incubating them with 3 mM
thymidine (Sigma-Aldrich) in McCoy's 5A medium. After
17 h incubation at 37°C, the cells were washed twice with
PBS and incubated in normal medium for an additional
12 h at 37°C to release them from the block. The cells
were then enriched for G1, S and GM phases by carrying
out the following steps: G1 (0.5 mM L-minosine (Sigma-
Aldrich) for 15 h); S phase (3 mM thymidine for 16 h);
and M phase (100 ng/ml nocodazole (Sigma-Aldrich) for
12 h). Cells were treated with trypsin or 4 mM EDTA and
fixed in 1% paraformaldehyde overnight at 4°C for flow
cytometry. DNA was stained with 0.01 mg/ml propidium
iodide in PBS containing 0.1% Triton X-100 and 0.1 mg/
mL RNase A for 1 h at 37°C in the dark. Stained cells were
analyzed using the FACScalibur™ flow cytometer (BD Bio-
sciences, Franklin Lakes, NJ).
Western blot
Western blot analyses was performed on HCT116 cell
lysates (7 μg/well) (Lee et al., 2003) using the rabbit anti-
FAT10 (Lee et al., 2003), and goat anti-actin (Santa Cruz
Biotechnology) primary antibodies and HRP-conjugated
anti-mouse or anti-goat IgG secondary antibodies (Pierce
Biotechnology). The Western blot membranes were visu-
alized by ECL Advance™ Western blotting detection kit
(Amersham Biosciences). Results were quantified through
densitometric analysis.
Quantitative real-time RT-PCR analysis
Total cellular RNA was isolated from HCT116 cells using
an RNeasy mini-kit (Qiagen). Quantitation of FAT10 and
β-actin transcript levels was performed as previously
reported [21]. Briefly, cDNA was synthesized from total
RNA using Superscript II reverse transcriptase (Invitrogen)
and real-time polymerase chain reaction (PCR) was per-
formed on the cDNA products in a Rotor-Gene 2000 Real-
Time Thermal Cycler (Corbett Research) using the Quant-
iTect™ SYBR® Green PCR Kit (Qiagen) and the following
primers:  FAT10 (F: 5'CAATGCTTCCTGCCTCTGTG, R:
5'TGCCTCTTTGCCTCATCACC);  β-actin (F: 5'ATGTTT-
GAGACCTTCACACC, R: AGGTAGTCAGTCAGGTCCCG-
GCC). The PCR reaction for FAT10 comprise of a
denaturation step at 95°C for 15 min followed by 45
cycles of amplification at 95°C for 30 sec, 64°C for 30 sec
and 72°C for 30 sec, while β-actin amplification involved
an initial denaturation at 95°C for 15 min followed by 40
cycles at 95°C for 30 sec, 55°C for 30 sec and 72°C for 30
sec. SYBR® Green fluorescence was measured after each
extension step. Standard curves for FAT10 and β-actin
were generated using serial dilution of plasmids contain-
ing the respective cDNAs. The linear range for all theCell Division 2006, 1:20 http://www.celldiv.com/content/1/1/20
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respective gene expression was determined to be between
103 to 108 copies (r2 for FAT10 is 0.9993; and β-actin is
0.992 respectively). FAT10 expression was normalized
against the housekeeping β-actin gene expression. All
experiments were performed in triplicate.
Construction of reporter plasmids
A series of different length fragments upstream the TLSS/
TSS of the FAT10 gene (+1/+209, -366/+209, -975/+209
and -1997/+209) were cloned into an expression vector
(pFAT10-EGFP) whereby the FAT10 promoter drives the
β-galactosidase (β-gal) reporter gene while the constitu-
tive cytomegalovirus (CMV) promoter drives the
enhanced green fluorescent protein (EGFP) reporter gene
(Fig. 1D) as described previously [21]. All constructs were
sequenced to exclude any PCR errors. Plasmid DNA was
prepared using an endotoxin-free Maxi Prep kit (Qiagen).
Transient transfection and β-galactosidase reporter assays
Two hundred thirty thousand HCT116 cells were seeded
onto each well of a 6-well plate the day before transfec-
tion. Transfection was carried out using Superfect reagent
(Qiagen) according to the manufacturer's instructions.
After 24-h incubation, cells were enriched for G1, S and M
phases by carrying out the steps as described above. Cells
were then washed with PBS and solubilized in 1x reporter
lysis buffer (Promega) and β-galactosidase activity was
determined in a kinetic assay as described previously [21].
Statistical and computational methods
Statistically significant differences between samples
means were determined by single-factor analysis of vari-
ance (ANOVA) followed by a post-hoc Tukey's test for
multiple pairwise comparisons. P < 0.05 was considered
significant.
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